Utility and safety of maintenance chemotherapy in advanced non–small cell lung cancer across various performance status categories: real-world experience-Reference-Cited by-同舟云学术

Utility and safety of maintenance chemotherapy in advanced non–small cell lung cancer across various performance status categories: real-world experience

Published:2020-06 Issue:3 Volume:44 Page:100565
ISSN:0147-0272
Container-title:Current Problems in Cancer
language:en
Short-container-title:Current Problems in Cancer

Author:

Prasad Kuruswamy Thurai^ORCID,Muthu Valliappan,Biswas Bivas,Malik Prabhat Singh,Dabkara Deepak,Ganguly Sandip^ORCID,Ghosh Joydeep,Kataria Babita,Khurana Sachin,Verma Saurav,Singh Navneet^ORCID

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference18 articles.

1. Systemic therapy for stage IV non-small-cell lung cancer: American Society of Clinical Oncology Clinical Practice Guideline Update;Hanna;J Clin Oncol,2017

2. Maintenance therapy for advanced lung cancer: who, what, and when?;Gerber;J Clin Oncol.,2013

3. Systemic therapy for stage IV non-small-cell lung cancer: American Society of Clinical Oncology Clinical Practice Guideline Update;Masters;J Clin Oncol,2015

4. A phase II study of pemetrexed monotherapy in chemo-naive Eastern Cooperative Oncology Group performance status 2 patients with EGFR wild-type or unknown advanced non-squamous non-small cell lung cancer (HANSHIN Oncology Group 002);Hata;Cancer Chemother Pharmacol,2015

5. Cisplatin and gemcitabine first-line chemotherapy followed by maintenance gemcitabine or best supportive care in advanced non-small cell lung cancer: a phase III trial;Brodowicz;Lung Cancer,2006

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Outcomes of Anlotinib Maintenance Therapy in Patients With Advanced NSCLC in a Real-World Setting;Frontiers in Oncology;2022-06-30

2. Risk factors of nephrotoxicity of maintenance pemetrexed in patients with metastatic non-squamous non-small cell carcinoma of lung;Lung Cancer;2021-12

3. Programmed death-ligand 1 expression and tumor-infiltrating lymphocytes in non-small cell lung cancer: association with clinicopathologic parameters;Journal of Pathology and Translational Medicine;2021-11-15

4. Lung Cancer in India;Journal of Thoracic Oncology;2021-08

5. Combined Methylome and Transcriptome Analyses Reveals Potential Therapeutic Targets for EGFR Wild Type Lung Cancers with Low PD-L1 Expression;Cancers;2020-09-03